Treatment of typical absence seizures and related epileptic syndromes

Paediatric Drugs

Volumn 3, Issue 5, 2001, Pages 379-403

  Panayiotopoulos, C P ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; CLONAZEPAM; ETHOSUXIMIDE; LAMOTRIGINE; VALPROIC ACID;

ABSENCE; CONSCIOUSNESS DISORDER; DIFFERENTIAL DIAGNOSIS; ELECTROENCEPHALOGRAM; EPILEPSY; HEREDITY; HYPERVENTILATION; MYOCLONUS EPILEPSY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SPIKE WAVE; TONIC CLONIC SEIZURE;

EID: 0034992257     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200103050-00006     Document Type: Review

References (162)

1. Proposal for revised clinical electroencephalographic classification of epileptic seizures
2. Differentiation of typical absence seizures in epileptic syndromes: A video EEG study of 224 seizures in 20 patients
3. Absence epilepsies
4. Typical absence seizures
5. Animal models of absence seizures and absence epilepsies
6. Pathophysiological mechanisms of genetic absence epilepsy in the rat
7. Mechanisms of generalized absence epilepsy
8. Generalized epilepsies: Emerging insights into cellular and genetic mechanisms
9. Typical absence seizures and their treatment
10. Inappropriate use of carbamazepine and vigabatrin in typical absence seizures
11. Importance of specifying the type of epilepsy
12. Proposal for revised classification of epilepsies and epileptic syndromes
13. Absence epilepsies
14. What are the relevant criteria for a better classification of epileptic syndromes with typical absences?
15. Childhood absence epilepsy
16. The outcome of absence epilepsy: A meta-analysis
17. Prognostic factors for childhood and juvenile absence epilepsies
18. Epilepsy with myoclonic absences
19. Myoclonic absence epilepsy
20. Impulsiv-Petit mal
21. Juvenile myoclonic epilepsy: A 5-year prospective study
22. Mapping and positional cloning of common idiopathic generalized epilepsies: Juvenile myoclonus epilepsy and childhood absence epilepsy
23. Absences in juvenile myoclonic epilepsy: A clinical and video- electroencephalographic study
24. Juvenile myoclonic epilepsy: A review
25. Eyelid myoclonia with absences in adults: A clinical and video-EEG study
26. Eyelid myoclonia with or without absences
27. Perioral myoclonia with absences: A case report with EEG and voltage mapping analysis
28. Perioral myoclonia with absences: A new syndrome
29. Typical absence status in adults: Diagnostic and syndromic considerations
30. Verlaufsformen kindlicher epilepsien mit spike wave-absencen
31. Absence epilepsy of early childhood: Genetic aspects
32. Absence epilepsy of early childhood
33. Idiopathic generalised epilepsy in adults manifested by phantom absences, generalised tonic-clonic seizures, and frequent absence status
34. Towards an understanding of reflex epilepsy and absence
35. Typical absences with specific modes of precipitation (reflex absences): Clinical aspects
36. Idiopathic generalised epilepsies in adults with onset of typical absences before the age of 10 years
37. Symptomatic typical absence seizures
38. Subependymal heterotopia: A distinct neuronal migration disorder associated with epilepsy
39. The epidemiology and prognosis of typical absence seizures
40. Survey of seizure disorders in the French southwest I. Incidence of epileptic syndromes
41. Epidemiology of absence epilepsy I: Concept and incidence
42. Incidence of epilepsy in children: A follow-up study three years after the first seizure
43. Familial occurrence of epilepsy in children with newly diagnosed multiple seizures: Dutch study of epilepsy in childhood
44. Classification of childhood epilepsy syndromes in newly diagnosed epilepsy: Interrater agreement and reasons for disagreement
45. Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures
46. Antiepileptic drug cellular mechanisms of action: Where does lamotrigine fit in?
47. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons
48. Studies of the lethargic (1h/1h) mouse model of absence seizures: Regulatory mechanisms and identification of the 1h gene
49. Action of anti-epileptic drugs in animal models: Mechanistic frame-work of absence seizures with a focus on the lethargic (1h/1h) mouse model
50. A receptor function in developing rat thalamic reticular neurons: Whole cell recordings of GABA-mediated currents and modulation by clonazepam
51. Evidence for a critical role of GABAergic transmission within the thalamus in the genesis and control of absence seizures in the rat
52. Functional imaging in idiopathic generalized epilepsy
53. Positron emission tomography receptor studies
54. Abnormal cerebral structure in juvenile myoclonic epilepsy demonstrated with voxel-based analysis of MRI
55. Quantitative MRI in patients with idiopathic generalized epilepsy. Evidence of widespread cerebral structural changes
56. The significance of microdysgenesia in primary generalized epilepsy: An answer to the considerations of Lyon and Gastaut
57. Epilepsies in twins: Genetics of the major epilepsy syndromes
58. Study of concordance of symptoms in families with absence epilepsies
59. Epilepsies in twins
60. Clinical and genetic analysis of a large pedigree with juvenile myoclonic epilepsy
61. Genetic mapping of a major susceptibility locus for juvenile myoclonic epilepsy on chromosome 15q
62. Genetics of inherited epilepsies
63. Reproducibility and complications in gene searches: Linkage on chromosome 6, heterogeneity, association, and maternal inheritance in juvenile myoclonic epilepsy
64. No evidence for a major susceptibility locus for juvenile myoclonic epilepsy on chromosome 15q
65. Evidence for linkage of adolescent-onset idiopathic generalized epilepsies to chromosome 8-and genetic heterogeneity
66. Childhood absence epilepsy with tonic-clonic seizures and electroencephalogram 3-4Hz spike and multispike-slow wave complexes: Linkage to chromosome 8q24
67. Genetic and phenotypic heterogeneity of inherited spike- and -wave epilepsies
68. Will a critical level of hyperventilation-induced hypocapnia always induce an absence seizure?
69. Typical absence seizures in adults: Clinical, EEG, video-EEG findings and diagnostic/syndromic considerations
70. Lamictal (lamotrigine) monotherapy for typical absence seizures in children
71. Consistent EEG focalities detected in subjects with primary generalized epilepsies monitored for two decades
72. Long-term prognosis of typical childhood absence epilepsy: Remission or progression to juvenile myoclonic epilepsy
73. Clinical and genetic aspects of juvenile absence epilepsy
74. Ethosuximide and valproate
75. Valproic acid in the treatment of intractable absence seizures in children: A single-blind clinical and quantitative EEG study
76. Effect of valproic acid on spike and wave discharges in patients with absence seizures
77. Valproate prevents the recurrence of absence status
78. Valproic acid: A reappraisal of its pharmacological properties and clinical efficacy in epilepsy
79. Treatment of generalized epilepsies of childhood and adolescence with sodium valproate ('epilim')
80. Sodium valproate: Monotherapy and polytherapy
81. Mechanisms of action of valproate: A commentatory
82. Antiepileptic drug mechanisms of action
83. Valproate: A reappraisal of its pharmacodynamic properties and mechanisms of action
84. Is valproate pharmacotherapy associated with polycystic ovaries?
85. Hematologic toxicity of sodium valproate
86. Valproic acid hepatic fatalities III: US experience since 1986
87. Consensus guidelines: Preconception counseling, management, and care of the pregnant woman with epilepsy
88. Benzodiazepine amplification of valproate teratogenic effects in children of mothers with absence epilepsy
89. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy
90. On the association between valproate and polycystic ovary syndrome
91. On the association between valproate and polycystic ovary syndrome: A response and an alternative view
92. Valproate and polycystic ovarian syndrome: Final thoughts
93. Sodium valproate acutely inhibits lamotrigine metabolism
94. Adding lamotrigine to valproate: Incidence of rash and other adverse effects
95. Valproic acid and ethosuximide interaction
96. Dramatic effect of ethosuximide on epileptic negative myoclonus: Implications for the neurophysiological mechanism
97. Treatment of epileptic falling spells with ethosuximide
98. Myoclonus and epilepsy in childhood: A review of treatment with valproate, ethosuximide, lamotrigine and zonisamide
99. Ethosuximide: Relation of plasma levels to clinical control
100. Ethosuximide: Relation of plasma levels to clinical control
101. Ethosuximide in the treatment of absence (peptit mal) seizures
102. Evaluation of treatment in typical absence seizures. The roles of long-term EEG monitoring and ethosuximide
103. Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal)
104. Valproic acid versus ethosuximide in the treatment of absence seizures
105. Comparison of ethosuximide with sodium valproate
106. Computer model of ethosuximide's effect on a thalamic neuron
107. Interaction of lamotrigine with sodium valproate
108. Lamotrigine monotherapy in children
109. Lamotrigine: A review of its use in childhood epilepsy
110. Efficacy of lamotrigine in idiopathic generalized epilepsy syndromes: A video-EEG-controlled, open study
111. Lamotrigine as an add-on drug in typical absence seizures
112. Lamotrigine in the treatment of absence seizures
113. The use of lamotrigine in juvenile myoclonic epilepsy
114. Lamotrigine in typical absence epilepsy
115. Lamictal (lamotrigine) monotherapy for typical absence seizures in children
116. Lamotrigine in absence and primary generalized epilepsies
117. Lamotrigine: A review of antiepileptic efficacy
118. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy
119. Lamotrigine for the treatment of epilepsy in childhood
120. Beneficial effect of relatively small doses of lamotrigine
121. Epilepsy with myoclonic absences
122. Lamotrigine: Clinical experience in 200 patients with epilepsy with follow-up to four years
123. Lamotrigine substitution study: Evidence for synergism with sodium valproate?
124. Disabling tremor after lamotrigine with sodium valproate
125. Lupus anticoagulant induced by the combination of valproate and lamotrigine
126. Potential hepatotoxicity of lamotrigine
127. Lamictal: Lamotrigine monotherapy for typical absence seizures in children
128. Effects of lamotrigine on absence seizures in rats
129. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy
130. A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure
131. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: A double-blind comparison with phenytoin
132. Lamotrigine monotherapy in epilepsy
133. Lamotrigine-associated rash: Risk/benefit considerations in adults and children
134. Lamotrigine: An update of its pharmacology and therapeutic use in epilepsy
135. Clinical effects and plasma concentrations of long-term clonazepam monotherapy in previously untreated epileptics
136. Clonazepam in juvenile myoclonic epilepsy
137. Clonazepam in the treatment of epilepsy: A controlled clinical trial in simple absences, bilateral massive epileptic myoclonus, and atonic seizures
138. Clonazepam
139. Treatment of epilepsy with clonazepam and its effect on other anticonvulsants
140. Clinical and EEG response to clonazepam in four patients with self-induced photosensitive epilepsy
141. Benzodiazepines in the treatment of epilepsy: A review
142. Clinical experience with clonazepam (rivotril) in the treatment of epilepsies in infancy and childhood
143. Clonazepam in the treatment of epilepsy
144. Serum clonazepam concentrations in children with absence seizures
145. Clonazepam in the treatment of absence seizures: A double blind clinical trial
146. Absence status and the concurrent administration of clonazepam and valproate sodium
147. Valproate and clonazepam comedication in patients with intractable epilepsy
148. Seizures with clonazepam: Discontinuation and suggestions for safe discontinuation rates in children
149. Long term follow-up of acetazolamide (diamox) in the treatment of epilepsy
150. Diamox in epilepsy: A review of 178 cases
151. Chronic acetazolamide monotherapy in the treatment of juvenile myoclonic epilepsy
152. Vigabatrin aggravates absences and absence status
153. Nonfocal generalized tonic-clonic seizures: Response during long-term topiramate treatment
154. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy
155. Exacerbation of seizures in children by carbamazepine
156. Absence seizures and carbamazepine in adults
157. Tiagabine and non-convulsive status epilepticus
158. Nonconvulsive status epilepticus in two patients receiving tiagabine treatment